The compound requires systematic assessment of effects on microglia-mediated neuroinflammation, amyloid-β pathology, tau phosphorylation, and cognitive outcomes in transgenic AD mice before clinical translation consideration. The gene discussed is MAPT; the disease is Alzheimer disease.